Rüter et al., 2010 - Google Patents
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumorsRüter et al., 2010
View PDF- Document ID
- 137042796607100051
- Author
- Rüter J
- Antonia S
- Burris H
- Huhn R
- Vonderheide R
- Publication year
- Publication venue
- Cancer biology & therapy
External Links
Snippet
Background: Single-dose infusion of the agonistic anti-CD40 monoclonal antibody (mAb) CP-870,893 accomplishes immune activation and clinical responses in patients with advanced cancers, but repeat dosing of this agent has not been reported. Patients and …
- 101710040446 CD40 0 title abstract description 50
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rüter et al. | Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors | |
| Whiteside | FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity | |
| Simon et al. | PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? | |
| Morrison et al. | Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity | |
| Binnewies et al. | Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity | |
| Minetto et al. | Harnessing NK cells for cancer treatment | |
| Ishikawa et al. | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer | |
| Lamichhane et al. | IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer | |
| Gao et al. | TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression | |
| Chauvin et al. | TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients | |
| Pierce et al. | In-situ tumor vaccination: bringing the fight to the tumor | |
| Fuertes et al. | Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells | |
| Romee et al. | Utilizing cytokines to function‐enable human NK cells for the immunotherapy of cancer | |
| Messaoudene et al. | Mature cytotoxic CD56bright/CD16+ natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma | |
| Barber et al. | Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| Perna et al. | Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma | |
| Zhulai et al. | Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy | |
| Bodduluru et al. | Natural killer cells: the journey from puzzles in biology to treatment of cancer | |
| Chan et al. | NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD | |
| Li et al. | Emerging immune checkpoints for cancer therapy | |
| Fasth et al. | Activating NK‐cell receptors co‐stimulate CD4+ CD28− T cells in patients with rheumatoid arthritis | |
| Banchereau et al. | Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming | |
| Karim et al. | Toll like Receptor 2 engagement on CD4+ T cells promotes TH9 differentiation and function | |
| Jiang et al. | The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy |